KURA241220P5000
- 0.03
- 0.000.00%
Kura Oncology Newsroom
Stifel Maintains Kura Oncology(KURA.US) With Hold Rating, Cuts Target Price to $11
Stifel Nicolaus Keeps Their Hold Rating on Kura Oncology (KURA)
Kura Oncology to Participate in JMP Securities Hematology and Oncology Summit
Analysts Are Bullish on These Healthcare Stocks: Kura Oncology (KURA), Bruker (BRKR)
Kura Oncology, Inc. (KURA): Among the Most Promising Cancer Stocks According to Hedge Funds
Kura Oncology Shares Are Trading Higher. B of A Securities Maintained a Buy Rating on the Stock.
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $18 to $34
Kura Oncology Analyst Ratings
Kura Oncology's Strategic Developments and Partnership With Kyowa Kirin Justify Buy Rating, Despite Initial Stock Dip
Express News | Kura Oncology Inc : BofA Global Research Cuts Price Objective to $29 From $36
Barclays Reaffirms Their Buy Rating on Kura Oncology (KURA)
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Analysts Supportive of Kura/Kirin Deal Despite Major Selloff in Shares
Kura Oncology Shares Are Trading Lower. The Company Announced It Entered Into a Global Strategic Collaboration With Kyowa Kirin to Develop and Commercialize Ziftomenib.
Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
Kura Oncology Tumbles as Kyowa Collaboration Seen Hitting M&A Prospects
Kura Oncology Is Maintained at Buy by Jefferies
Express News | Kura Oncology Shares Fall 26.5% After Co to Partner With Kyowa Kirin for Blood Cancer Therapy
Kura Oncology's Commercialization Deal Isn't What Investors Wanted -- Market Talk
Kura Oncology (KURA) Receives a Buy From Wedbush